Blueprint Medicines Corp. (BPMC)

74.25
0.55 0.75
NASDAQ : Health Technology
Prev Close 73.70
Open 73.95
Day Low/High 72.79 / 74.98
52 Wk Low/High 44.58 / 109.00
Volume 339.71K
Avg Volume 296.70K
Exchange NASDAQ
Shares Outstanding 43.95M
Market Cap 3.39B
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy And Outlines Key Corporate Goals

Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy And Outlines Key Corporate Goals

-- Top-line avapritinib data support planned NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST in first half 2019 --

First Week Of BPMC July 2019 Options Trading

First Week Of BPMC July 2019 Options Trading

Investors in Blueprint Medicines Corp saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 207 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Blueprint Medicines Announces Updated NAVIGATOR Trial Results In Patients With Advanced Gastrointestinal Stromal Tumors Supporting Development Of Avapritinib Across All Lines Of Therapy

Blueprint Medicines Announces Updated NAVIGATOR Trial Results In Patients With Advanced Gastrointestinal Stromal Tumors Supporting Development Of Avapritinib Across All Lines Of Therapy

- 84% ORR in PDGFRα D842V GIST and 20% ORR in fourth-line or later GIST support plans to submit New Drug Application to FDA in the first half of 2019 -

Blueprint Medicines Reports Third Quarter 2018 Financial Results

Blueprint Medicines Reports Third Quarter 2018 Financial Results

- Avapritinib receives Breakthrough Therapy Designation for treatment of advanced SM -

Blueprint Medicines Announces Proof-of-Concept Data Showing Combination Of BLU-667 And Osimertinib Overcame Treatment Resistance In Two Patients With EGFR-Mutant, Non-Small Cell Lung Cancer And An Acquired RET Fusion

Blueprint Medicines Announces Proof-of-Concept Data Showing Combination Of BLU-667 And Osimertinib Overcame Treatment Resistance In Two Patients With EGFR-Mutant, Non-Small Cell Lung Cancer And An Acquired RET Fusion

-- Data presented at Late-Breaking Clinical Session of IASLC World Conference on Lung Cancer, and simultaneously published in Cancer Discovery --

Blueprint Medicines Corp Larger Than S&P 500 Component News Corp

Blueprint Medicines Corp Larger Than S&P 500 Component News Corp

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Blueprint Medicines Corp was identified as having a larger market cap than the smaller end of the S&P 500, for example News Corp , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

First Week Of BPMC February 2018 Options Trading

First Week Of BPMC February 2018 Options Trading

Investors in Blueprint Medicines Corp saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BPMC options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.

Blueprint Medicines Reaches Analyst Target Price

Blueprint Medicines Reaches Analyst Target Price

In recent trading, shares of Blueprint Medicines Corp have crossed above the average analyst 12-month target price of $55.60, changing hands for $55.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Blueprint Medicines Becomes Oversold (BPMC)

Blueprint Medicines Becomes Oversold (BPMC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting BPMC Put And Call Options For August 18th

Interesting BPMC Put And Call Options For August 18th

Investors in Blueprint Medicines Corp saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BPMC options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIG, ALSK, GNE, GUID, HTH, LPI, NUVA, PIRS, QRVO, S, TTMI Downgrades: ARRS, BPMC, CONE, CRAY, EFII, GIL, GKOS, HYH, SUM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

BPMC Crosses Above Average Analyst Target

In recent trading, shares of Blueprint Medicines Corp have crossed above the average analyst 12-month target price of $46.75, changing hands for $48.49/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Analysts' Actions -- Boeing, Blueprint Medicines, Rockwell Collins, Johnson Controls and More

Analysts' Actions -- Boeing, Blueprint Medicines, Rockwell Collins, Johnson Controls and More

Here are Monday's top research calls, including upgrades for Blueprint Medicine, Gartner and Rockwell Collins and a downgrade for Boeing.

Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez

Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez

Cempra, Blueprint Medicines and  Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Monday.

6 Stocks on the Move With Huge Volume

6 Stocks on the Move With Huge Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.

Interesting BPMC Put And Call Options For February 2017

Interesting BPMC Put And Call Options For February 2017

Investors in Blueprint Medicines Corp saw new options become available this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BPMC options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers

Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers

Shares tanked Wednesday on little more than a two-sentence comment from the president-elect.

Notable Wednesday Option Activity: BPMC, LGF, CVI

Notable Wednesday Option Activity: BPMC, LGF, CVI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Blueprint Medicines Corp , where a total of 1,350 contracts have traded so far, representing approximately 135,000 underlying shares. That amounts to about 42.6% of BPMC's average daily trading volume over the past month of 317,250 shares.

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

There's little to substantiate the president-elect's claim that he will bring drug prices down, but biotech investors are trading anyway.

TheStreet Quant Rating: D (Sell)